

Important Medical Events: Current Status and Maintenance Principles

Patricia Mozzicato, MD
MedDRA MSSO

15 November 2011




Topics Covered



- Background of IME list
 - What is the IME List?
 - Purpose of IME List
- IME List survey results
- Considerations in maintaining MedDRA-based term lists
 - Inclusion/exclusion criteria
 - Version updates
 - Recent developments

MedDRA is a clinically-validated international medical terminology used by regulatory authorities and the regulated biopharmaceutical industry. The terminology is used through the entire regulatory process, from pre-marketing to post-marketing, and for data entry, retrieval, evaluation, and presentation.

3



4

Background of IME List

What Is the IME List?

- List of MedDRA Preferred Terms (PTs)
- Development coordinated by the Eudravigilance Expert Working Group (EV-EWG)
- Updated with each release of MedDRA
- User input is collected and assessed for version updates

- Reference: “Eudravigilance Important Medical Event Terms (IME) List (30 July 2009)
 - EMEA/457378/2008
 - http://eudravigilance.ema.europa.eu/human/docs/Explanatory_note_IME_list.pdf
- Facilitate:
 - Classification of suspected adverse reactions
 - Aggregate data analysis
 - Case assessment for pharmacovigilance activities
- Intended for **guidance purposes only**
 - Not mandatory requirement for regulatory reporting
 - Option to use it for other purposes

7

- **All terms** in three SOCs initially INCLUDED:
 - SOC *Congenital, familial and genetic disorders*
 - SOC *Infections and infestations*
 - SOC *Neoplasms benign, malignant and unspecified (incl cysts and polyps)*
- **All terms** in two SOCs initially EXCLUDED:
 - SOC *Social circumstances*
 - SOC *Surgical and medical procedures*
- Remaining terms in 21 SOCs were assessed by volunteers with medical background


8

- Divided terms for inclusion into:
 - “Core serious” (CS) – always serious
 - “Extended serious” (ES) – serious in some circumstances only
- Teams of 4 – 6 volunteers reviewed the terms:
 - If majority agreed, term added
 - If “tie”, the more conservative assessment was taken (e.g., if 3 for CS and 3 for ES, term became CS)

IME List Survey Results


- All stakeholders who requested the IME list were invited to participate
- Survey created by EV-EWG
- Run from May – October 2010
 - 35 responders
- Objective was to assess:
 - Type of users who tested the IME list
 - How IME list has been tested
 - How useful IME list has been
 - How to improve IME list in the future
- **(Data on the following slides were kindly provided by EMA)**

11




12

IME List Survey – Usefulness




13

IME List Survey – Strengths



14



Maintaining MedDRA-based Term Lists

Term lists maintained by MedDRA MSSO

- Gender-Specific Adverse Events
- Pediatric Adverse events
- Standardised MedDRA Queries (SMQs)

17

- Understand **purpose** of list
 - What is the intended use of the list?
 - Are there other ways the list may be used?
- Understand **scope** of list
 - What are the inclusion/exclusion criteria?

18

- List received for review in MedDRA v12.0; approx. 9000 PTs
- To update list to MedDRA v12.1, first inclusion/exclusion criteria needed to be developed
- Draft incl/excl criteria:
 - Overall
 - SOC-specific

19

- Inclusion/exclusion criteria based on **ICH definition of an IME**
*“...may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed **in the definition above.**”*

20

- Overall
 - Included
 - Generally, all infarct/infarction terms (e.g., PT *Renal infarct*)
 - Terms for failure or insufficiency of life-sustaining organ systems (PT *Hepatic failure*)
 - Excluded
 - “Pain” and “discomfort” terms (PT *Pain of skin*)

21

- SOC *Cardiac disorders*:
 - Included
 - All terms for cardiac valve disorders (e.g., PT *Aortic valve stenosis*)
 - All terms for endocardial disorders (PT *Endocardial fibrosis*)
 - Excluded
 - Terms for trivial arrhythmias that do not lead to more significant consequences (PT *Extrasystoles*)

22

- Core serious
 - Precisely fits definition of an IME
 - Example: PT *Stroke in evolution*
- Extended serious
 - Does not precisely fit definition
 - Sometimes rather broad concept
 - *With additional clinical information*, may be or evolve into an IME
 - Example: PT *Anaemia*

23

- Original scope of IME list changed
 - **Selected** (not all) PTs from these SOC are included:
 - SOC *Congenital, familial and genetic disorders*
 - SOC *Infections and infestations*
 - SOC *Neoplasms benign, malignant and unspecified (incl cysts and polyps)*
 - **Selected** PTs from these SOC are included (had originally been excluded):
 - SOC *Social circumstances*
 - SOC *Surgical and medical procedures*

24

- Apply inclusion/exclusion criteria to **new** PTs
- Check for other PT changes (demotion to LLT, change of primary SOC)
- Address input from stakeholders
- EV-EWG reviews updated lists and criteria with each new version

25

- Size of list (Version 14.1)
 - PTs in MedDRA = 19,294
 - PTs on IME List = 10,372 (54% of all MedDRA PTs)
 - “Core Serious” PTs = 7547 (39% of all MedDRA PTs; 73% of PTs on IME list)
 - “Extended Serious” PTs = 2825
- Application of “Extended Serious” criterion
- Consistency (e.g., some diabetes terms CS, others ES)

26

- Current definition:

Such PTs do not precisely fit the definition and are sometimes rather broad (e.g., terms for “disorders” of vital organs). Although the term in isolation may not represent a clear cut IME, it could be envisioned that – *with additional clinical information and medical circumstances (medical history, age of patient, etc.) available to the recipient of the report* – the event may be or evolve into an IME.

- Challenging to apply this criterion *to MedDRA terms* (devoid of the needed context)

27

- Almost any event – with additional information known by recipient – could be ES. For example:
 - A headache could be sudden, disabling and severe enough for hospital visit
 - Implant site inflammation could result in disability if unable to use limb
- What is the value of ES terms?

28

- EMA and EV-EWG agreed that ES terms will be dropped from IME list
- Consistency issues will be addressed at a future date

29

Thank You

30